Image analysis (DNA ploidy) and expression of c-erb B-2 and p5 3 in imprint smears of breast cancer

Purpose of investigation: To co-evaluate DNA analysis and the expression of c-erb B-2 and p53 oncoproteins with the histologic type and the other known prognostic factors of breast cancer.

Methods: Sixty-five imprint smears from breast surgical specimens were examined by immunocytochemical staining for c-erb B-2 and p53 and routine pap staining. The immunostaining was considered positive for c-erb B-2 if the cancer cells showed specific membrane staining and for p53 specific nuclear staining. In 30 breast carcinoma imprints, DNA ploidy was evaluated by an image analysis technique using a SAMBA 2005 analyser.

Results: From the total number of 53 breast carcinomas which were evaluated in our study 25 (47.1%) showed c-erb B-2 immunopositivity, while 16 (30.18%) exhibited p53 positive nuclear immunoreactivity. Ten out of 13 (76.92%) aneuploid breast carcinomas were positive for c-erb B-2 while five out of 13 (38.46%) showed immunopositivity for p53.

Conclusion: From our findings it seems that detection of c-erb B-2 and p53 expression in samples of breast carcinomas could be an important prognostic factor and may identify patients with more aggressive disease.

Breast carcinoma; c-erb B-2; p53; DNA ploidy; Fine needle aspirates

[1] Yetrani A., Fulcin山F., Di Benedetto G. et al.: "Fine-needle asp,ration biopsies of breast masses. An additional experience with 1153 cases (1985-1988) and a meta-analysis". Cancer, 1992, 69, 736.

[2] Spandidos D.A., Anderson M.L.M.: "Oncogenes and oncosuppressor genes: T heir involvement in cancer". J. Path., 1989, 157, 1.

[3] Bozzetti C., Nizzoli R., Naldi N., Menotti L., Savoldi L., Camisa R, et al.: "Fine-needle aspiration technique for the concurrent immunocytochemical evaluation of multiple biologic parameters in primary breast carcinoma". Breast Cancer Res. Treat., 1994, 32, 221.

[4] Fernando I.N., Allan S.M., Sandie J., Dean C., Sacks N., Trott P.A.: "Immunocytochemical staining for the c-erb B-2 gene product in breast aspirates: a preliminary report". Cytopathology, 1993, 4, 219.

[5] Slamon DJ., Godolphin W., Jones L.A. et al.: "Studies of the HER-2/ new proto-oncogene in human breast and ovarian cancer" Science, 1989, 244, 707.

[6] Gullick W.J., Love S.B., W right C. et al.: "c-erb B-2 protem overexpression in breast cancer is a risk factor in patients with involved and uninvolved lymph nodes". Br. J. Cancer, 1991, 63, 434.

[7] Ioakim-Liossi A., Markopoulos C., Karakitsos P., Safioleas M., Gogas J., Vaiopoulos G.: "p53 protein expression in benign and malignant breast lesions". Acta Cytologica, 1998, 42 (4), 918.

[8] Colecchia M., Frigo B., Zucchi, A., Leopardi 0.: "p53 protem expression in fine-needle aspirates of breast cancer: An immunocytochemical assay for identifying high-grade ductal carcinomas". Diagn. Cytopath., 1995, 13 (2), 128.

[9] Tiniakos D.G., Robinson K.B., Greenwood H., Cullen P., Cook A I. M., Horne C. H. W., Angus B.: "c-erb B-2 and p53 expression in breast cancer fine needle aspirates". Cytopath., 1996, 7, 178..

[10] Koutselini H., Malliri A., Field J. K., Spandidos D. A.: "p53 expression in cytologic specimens from benign and malignant breast lesions". Anticancer Res., 1991, 11, 1415.

[11] Silvestrini R., Benini E., Daidone M.G., Yeroni S., Boracchi P., Capelleti V. et al.: "p53 as an independent prognostic marker in lymph node-negative breast cancer patients". J. Natl. Cancer Inst., 1993, 85, 965.

[12] Thor A.D., Moore D.H. II, Edgerton S.M., Kawasaki E.S., Reinhsaus E., Lynch H.T. et al:: "Accumulation of P.53 tumor surpressor gene protein: An independent marker of prognosis in breast cancer". J. Natl. Cancer Inst., 1992, 84, 845.

[13] Jaszez-Gruchala A., Swiatkiewiez I., Lackowska B., Gruchala A., Niezabitowski A.: "Comparative analysis of DNA content estimated by flow and image cytometry in breast tumor samples". Pol J. Pathol., 2001, 52 (1-2), 15.

[14] Klorin G., Keren R.: "P rognostic evaluation of breast cancer in cytologic specimens". Anal. Quant. Cytol. Histol., 2002, 24 (1), 49.

[15] Smith F.C., Leal C., Lopes C.: "p53 protein expression and nuclear DNA content in breast intraductal proliferations". J. Pathol., 1995, 233.

[16] Ioakim-Liossi A., P antazopoulos D., Karakitsos P., Athanassiadou P., Aroni K., Chourdakis N. et al.: "DNA ploidy and p53 protein expession in superficial transitional cell carcinoma of the bladder" Cytopathology, 2000, 11 (2), 96.

[17] Spiethoff A., Schenck A., Bohrer M.: "Relationship of DNA ploidy to hormone receptor status and proliferation in invasive breast carcinoma". J. Cancer Res. Clin. Oncol., 2000, 126 (12), 707.

[18] Rudolph P., Olsson H., Bonatz G., Ratjen V., Bolte H., Baldetorp B. et al.: "Correlation between p53, c-erb B-2 and topoisomerase II alpha expression, DNA ploidy, hormonal receptor status and proliferation in 356 node- negative breast carcinomas: prognostic implications". J. Pathol., 1999, 187 (2), 207.

[19] Troncone G., Zeppa P., Fulciniti F. et al.: "C-erb B-2 expression and DNA ploidy status in breast cancer cells obtained by fine needle aspiration (FNA)". Cytopathology, 1993, 4, 195.

[20] Wright C.. Nicholson S., Angus B. et al.: "Relationship between c-erb B-2 protein product expression and response to endocrine therapy in advanced breast cancer". Br. J. Cancer, 1992, 65, 118.